GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Other Gross PPE

Adagene (FRA:978) Other Gross PPE : €2.62 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Other Gross PPE?

Adagene's Other Gross PPE for the quarter that ended in Dec. 2023 was €2.62 Mil.

Adagene's quarterly Other Gross PPE declined from Dec. 2022 (€2.76 Mil) to Jun. 2023 (€2.32 Mil) but then increased from Jun. 2023 (€2.32 Mil) to Dec. 2023 (€2.62 Mil).

Adagene's annual Other Gross PPE increased from Dec. 2021 (€2.67 Mil) to Dec. 2022 (€2.76 Mil) but then declined from Dec. 2022 (€2.76 Mil) to Dec. 2023 (€2.62 Mil).


Adagene Other Gross PPE Historical Data

The historical data trend for Adagene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Other Gross PPE Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial 1.24 1.54 2.67 2.76 2.62

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.67 3.29 2.76 2.32 2.62

Adagene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Adagene (FRA:978) Business Description

Traded in Other Exchanges
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene (FRA:978) Headlines

No Headlines